Aldeyra Therapeutics Reports Positive Liver Function Results for ADX-629; Refocuses Pipeline on Next-Generation RASP Modulators

Aldeyra Therapeutics Reports Positive Liver Function Results for ADX-629; Refocuses Pipeline on Next-Generation RASP Modulators

By, Admin 31 October 2025

Aldeyra Therapeutics Inc., a biotechnology company focused on developing therapies for immune-mediated diseases, announced statistically significant improvements in liver function among patients treated with ADX-629, an investigational RASP modulator. The company also outlined plans to prioritize next-generation candidates ADX-248 and ADX-246 within its RASP modulator pipeline.

Phase 2 Results for ADX-629

In a single-arm, multicenter Phase 2 clinical trial, ADX-629 was administered orally for one month to four patients with mild to moderate alcohol-associated hepatitis.

Compared with baseline, patients demonstrated statistically significant improvement in key markers of liver function and inflammation, including:

  • Model for End-Stage Liver Disease (MELD) score: P=0.001
  • Triglyceride levels: P<0.0001
  • C-Reactive Protein (CRP) levels: P<0.0001

No serious adverse events were reported, and no adverse events were attributed to ADX-629.

“Consistent with earlier trials in atopic dermatitis, psoriasis, chronic cough, and asthma, ADX-629 demonstrated measurable improvements in liver function and inflammation,” said Todd C. Brady, President and CEO of Aldeyra Therapeutics. “These results mark the culmination of ADX-629’s proof-of-concept work as we advance our next-generation RASP modulators for immune-mediated diseases.”

Pipeline Realignment

Following the completion of ADX-629’s clinical program, Aldeyra has redirected focus toward its newer candidates:

  • ADX-248: A next-generation RASP modulator for metabolic inflammation, including obesity and hypertriglyceridemia, showing high exposure with once-daily dosing in Phase 1 trials. An Investigational New Drug (IND) application is expected in 2026.
  • ADX-246: A RASP modulator for dry age-related macular degeneration (dry AMD), selected following favorable preclinical data. IND submission is also anticipated in 2026.

Clinical development of ADX-629 will be discontinued, except for potential investigator-sponsored studies in Sjögren-Larsson Syndrome, a RASP-mediated metabolic disorder.

Financial Outlook

Aldeyra stated that following these pipeline adjustments, its operational runway—based on current cash, cash equivalents, and marketable securities—has been extended into the second half of 2027.

“In addition to our late-stage, pre-commercial programs in ophthalmic and rare diseases, Aldeyra remains committed to building a sustainable pipeline of novel therapeutics,” added Dr. Brady. “We continue to execute our development strategy in a fiscally disciplined manner to support long-term growth.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!